---
layout: post
title: "八大券商主题策略：“吃药”行情又起风！CXO、中药、医疗器械等细分龙头梳理"
date: 2022-02-15 12:06:55 +0800
categories: emnews
tags: 东财滚动新闻
---
> 中航证券表示，长期来看，随着药品、耗材带量采购工作持续推进，安全边际高、创新能力强、产品管线丰富和竞争格局较好的企业有望在长周期持续受益，建议继续围绕创新药产业链、高端医疗器械、医疗服务和医疗消费布局，同时挖掘估值相对较低的二线蓝筹。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" data-code="BK1041|90|1" data-code2="BK1041|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1041&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1041_0" data-code="K BK1041|90|1" data-code2="K BK1041|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25419574617203185500_w633h638.jpg" width="580" emheight="585" orginial_src="https://dfscdn.dfcfw.com/download/D25419574617203185500_w633h638_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong><span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>：看好CXO行情！看好<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>CDMO供应链持续超预期可能性</strong></p><p>CXO估值底部逐步显现，目前CXO板块普遍处于历史估值底部，在外部催化不断，内部经营质量和海外大客户认可度持续提升前景下，看好CXO行情。</p><p>看好<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>CDMO供应链持续超预期可能性。复盘2021Q4<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>和<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>陆续<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>与海外大型制药企业(我们预计是<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠治疗药物相关)CDMO大体量订单分别达到约9亿美金和2.14亿美金，此次<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>进一步追加6.81亿美金也彰显本土CDMO生产能力、质量体系和交付效率等在海外大药企供应链体系中较高认同度。我们看好本土CDMO供应能力获得海外大客户认可后承接更多海外其他创新药项目CDMO订单的可能性，以及在疫情持续未得到有效控制下，本土CDMO供应链<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>持续超预期可能性。考虑到目前CXO企业估值回落到2019年低位以及业绩确定性，重点推荐<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>和<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>。</p><p>投资建议来看，重点推荐：有望持续受益辉瑞新冠治疗药物CDMO产业链的<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、博腾股份等。估值底部积极进行<span id="Info.3285"><a href="http://data.eastmoney.com/gphg/" class="infokey">回购</a></span>的临床CRO龙头<span id="stock_0.300347"><a href="http://quote.eastmoney.com/unify/r/0.300347" class="keytip" data-code="0,300347">泰格医药</a></span><span id="quote_0.300347"></span>。估值性价比较高CXO龙头<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>、<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>等。重点关注：自主可控新冠治疗药物创新药企业<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、<span id="stock_0.002317"><a href="http://quote.eastmoney.com/unify/r/0.002317" class="keytip" data-code="0,002317">众生药业</a></span><span id="quote_0.002317"></span>、<span id="stock_0.300436"><a href="http://quote.eastmoney.com/unify/r/0.300436" class="keytip" data-code="0,300436">广生堂</a></span><span id="quote_0.300436"></span>、歌礼制药等，关注<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>新冠治疗方向的<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121321302336&direct=1&abc8358.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_0.002500"><a href="http://quote.eastmoney.com/unify/r/0.002500" class="keytip" data-code="0,002500">山西证券</a></span><span id="quote_0.002500"></span>：国内CXO行业高速发展 建议关注行业龙头及细分龙头</strong></p><p>行业整体估值处于历史最低水平，产业发展趋势向好，建议把握中短期回调机会。长期来看，带量采购常态化持续加速行业分化，倒逼企业向创新转型；医保目录动态调整，持续加速创新药放量。政策、人才、资本等推动下，我国创新药已进入成果收获期，并开启国际化之路。</p><p>建议关注创新及产业链相关细分领域：(1)目前国内创新药研发同质化较为严重，靶点、适应症较为集中，行业已逐步从me-too/me-worse 向更高质量、更具创新性的 me-better、first-in-class转型升级，研发实力雄厚，管线丰富，梯度合理，产品差异化优势突出的国产创新龙头企业优势将进一步凸显，建议关注<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span>等。</p><p>(2)国内疫苗行业持续处于高景气状态， 技术加速迭代升级，重磅产品陆续上市，国产创新疫苗已成为推动行业市场持续增长的支撑点。行业集中度持续提升，我们建议关注具有上市(包括代理)、在研重磅或独家产品，生产及研发实力兼具的优质疫苗龙头企业<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>等。</p><p>(3)随着科技的进步， 医疗新发现、新技术、新领域不断涌现， 细胞与基因治疗等生物新兴市场快速发展，建议关注各产业发展动态、优质企业及上游产业链如生命科学服务等。</p><p>(4)全球及国内创新药研发火热，国内CXO行业高速发展，预计随着政策推进、技术水平的持续提升，行业集中度有望进一步提升，建议关注行业龙头及细分龙头。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121335349871&direct=1&abc6991.pdf">【点击查看研报原文】</a></p><p><strong>中航<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：建议围绕创新药产业链、高端<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>等布局 挖掘估值相对较低的二线蓝筹</strong></p><p>随着经济政策底的确认和新一轮稳增长周期的到来，我们认为市场修复的重心或持续聚焦具备边际改善和估值修复逻辑的板块，在估值切换渐行渐近的时点，提前布局尤其需要关注边际改善和成长的可持续性。从估值角度来看，医药行业目前处于历史估值低位。市场一直担心集采和医保谈判对价格段的压制，会改变医药行业的成长属性，我们认为在需求确定的情况下，医药行业长期平稳增长的逻辑不变。</p><p>长期来看，随着药品、耗材带量采购工作持续推进，安全边际高、创新能力强、产品管线丰富和竞争格局较好的企业有望在长周期持续受益，建议继续围绕创新药产业链、高端<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>、<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>和医疗消费布局，同时挖掘估值相对较低的二线蓝筹：1)创新药及创新药产业链，包括综合类和专科创新药企业、CXO产业，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/1.600276" class="em_stock_key_common" data-code="1,600276">恒瑞医药</span>、博腾制药、<span id="stock_0.002262"><a href="http://quote.eastmoney.com/unify/r/0.002262" class="keytip" data-code="0,002262">恩华药业</a></span><span id="quote_0.002262"></span>、<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600196" class="em_stock_key_common" data-code="1,600196">复星医药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300347" class="em_stock_key_common" data-code="0,300347">泰格医药</span>、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>和<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>等；2)进口替代能力突出的高端<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>龙头，建议关注<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>和<span id="stock_0.300003"><a href="http://quote.eastmoney.com/unify/r/0.300003" class="keytip" data-code="0,300003">乐普医疗</a></span><span id="quote_0.300003"></span>等；3)受益市场集中度提升的医疗消费终端，建议关注<span id="stock_0.002727"><a href="http://quote.eastmoney.com/unify/r/0.002727" class="keytip" data-code="0,002727">一心堂</a></span><span id="quote_0.002727"></span>、<span id="stock_1.603939"><a href="http://quote.eastmoney.com/unify/r/1.603939" class="keytip" data-code="1,603939">益丰药房</a></span><span id="quote_1.603939"></span>和<span id="stock_0.300244"><a href="http://quote.eastmoney.com/unify/r/0.300244" class="keytip" data-code="0,300244">迪安诊断</a></span><span id="quote_0.300244"></span>等；4)具备稀缺性和消费属性的<span id="bk_90.BK1044"><a href="http://quote.eastmoney.com/unify/r/90.BK1044" class="keytip" data-code="90,BK1044">生物制品</a></span><span id="bkquote_90.BK1044"></span>企业，包括<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>、<span id="stock_0.002007"><a href="http://quote.eastmoney.com/unify/r/0.002007" class="keytip" data-code="0,002007">华兰生物</a></span><span id="quote_0.002007"></span>、<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺-U</a></span><span id="quote_1.688185"></span>和<span id="stock_0.000403"><a href="http://quote.eastmoney.com/unify/r/0.000403" class="keytip" data-code="0,000403">派林生物</a></span><span id="quote_0.000403"></span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121350458561&direct=1&abc5125.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>：四大<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产业投资逻辑！产业链标的曝光</strong></p><p>四大<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产业投资逻辑：1)国务院、国家药监局及医保局发文强烈支持中药产业，中药产业面临黄金发展期；2)中药治疗慢病及未病具有天然优势，在老龄化及消费升级背景下，中药的消费属性促使其快速放量；3)国标提升、中药饮片价格上涨，中药配方颗粒及OTC类产品提价导致毛<span id="Info.344"><a href="http://data.eastmoney.com/cjsj/yhll.html" class="infokey">利率</a></span>提升；4)板块多年未涨，表现为估值底、位置低及筹码结构好。建议关注标的：1)中药配方颗粒，建议关注<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>等；2)OTC类中药，建议关注<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="stock_1.600566"><a href="http://quote.eastmoney.com/unify/r/1.600566" class="keytip" data-code="1,600566">济川药业</a></span><span id="quote_1.600566"></span>、<span id="stock_1.600572"><a href="http://quote.eastmoney.com/unify/r/1.600572" class="keytip" data-code="1,600572">康恩贝</a></span><span id="quote_1.600572"></span>、<span id="stock_1.600436"><a href="http://quote.eastmoney.com/unify/r/1.600436" class="keytip" data-code="1,600436">片仔癀</a></span><span id="quote_1.600436"></span>等；3)创新类处方药，建议关注<span id="stock_0.300181"><a href="http://quote.eastmoney.com/unify/r/0.300181" class="keytip" data-code="0,300181">佐力药业</a></span><span id="quote_0.300181"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span id="stock_1.600557"><a href="http://quote.eastmoney.com/unify/r/1.600557" class="keytip" data-code="1,600557">康缘药业</a></span><span id="quote_1.600557"></span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121402520870&direct=1&abc2469.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.600958"><a href="http://quote.eastmoney.com/unify/r/1.600958" class="keytip" data-code="1,600958">东方证券</a></span><span id="quote_1.600958"></span>：特效药国产化值得期待 相关产业变化值得关注</strong></p><p>辉瑞特效药获批，国内疫情常态化将成为趋势。长期看，国内防控政策有望放宽。目前海外已对疫情保持放开的态度，考虑到Paxlovid主要活性成分奈马特韦在体外对变异毒株的抗病毒效果一致，对omicron等突变株产生疗效，且Paxlovid作为小分子药物可以口服，治疗方式方便可控。我们认为，国内的防控政策有望在有序的前提下逐步放宽，长期来看打开国门将是趋势。</p><p>特效药国产化值得期待，相关产业变化值得关注。一方面，新冠特效药在国内有巨大的市场前景，Paxlovid已在全球10多个国家被批准或授权紧急使用，产能不可能满足全部市场，且新冠药物具有战略重要性，国产化新冠特效药值得期待，在研的小分子管线有望通过应急获批加速上市；国内具备研发能力、原料药一体化的企业将受益，口服新冠特效药的获批有望加快国内小分子特效药的研发。</p><p>另一方面，辉瑞的Paxlovid需要大量的卡龙酸酐等API，利好国内原料药公司，如<span id="stock_0.300261"><a href="http://quote.eastmoney.com/unify/r/0.300261" class="keytip" data-code="0,300261">雅本化学</a></span><span id="quote_0.300261"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>等。已经有部分国内CDMO企业获得相关生产订单，如博腾股份、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>等，预计随着产能进一步扩张，相关CDMO企业还有望受益。</p><p>投资建议与投资标的来看，建议关注：<span id="stock_1.688180"><a href="http://quote.eastmoney.com/unify/r/1.688180" class="keytip" data-code="1,688180">君实生物-U</a></span><span id="quote_1.688180"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300261" class="em_stock_key_common" data-code="0,300261">雅本化学</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002349" class="em_stock_key_common" data-code="0,002349">精华制药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>、博腾股份、<span id="stock_1.688166"><a href="http://quote.eastmoney.com/unify/r/1.688166" class="keytip" data-code="1,688166">博瑞医药</a></span><span id="quote_1.688166"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000739" class="em_stock_key_common" data-code="0,000739">普洛药业</span>等公司。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121415083922&direct=1&abc4340.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.601788"><a href="http://quote.eastmoney.com/unify/r/1.601788" class="keytip" data-code="1,601788">光大证券</a></span><span id="quote_1.601788"></span>：基于医药投资的变与不变 未来应当积极把握创新化和国际化方向的投资机会</strong></p><p>基于医药投资的变与不变，我们认为未来应当积极把握创新化和国际化方向的投资机会。创新药与疫苗方面，推荐<span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>(H)、荣昌生物(H)；CXO方面，推荐<span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>(H)、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300759" class="em_stock_key_common" data-code="0,300759">康龙化成</span>、<span id="stock_1.688131"><a href="http://quote.eastmoney.com/unify/r/1.688131" class="keytip" data-code="1,688131">皓元医药</a></span><span id="quote_1.688131"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300725" class="em_stock_key_common" data-code="0,300725">药石科技</span>；器械设备与生命科学领域，推荐<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、<span id="Info.116.00853"><a href="http://quote.eastmoney.com/unify/r/116.00853" class="keytip" data-code="116,00853">微创医疗</a></span>(H)、<span id="stock_1.600587"><a href="http://quote.eastmoney.com/unify/r/1.600587" class="keytip" data-code="1,600587">新华医疗</a></span><span id="quote_1.600587"></span>、<span id="stock_0.300685"><a href="http://quote.eastmoney.com/unify/r/0.300685" class="keytip" data-code="0,300685">艾德生物</a></span><span id="quote_0.300685"></span>、<span id="stock_1.688301"><a href="http://quote.eastmoney.com/unify/r/1.688301" class="keytip" data-code="1,688301">奕瑞科技</a></span><span id="quote_1.688301"></span>；创新前沿技术方面，关注艾博生物等未上市企业；内需消费方面，推荐<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>(H)、<span id="stock_1.603883"><a href="http://quote.eastmoney.com/unify/r/1.603883" class="keytip" data-code="1,603883">老百姓</a></span><span id="quote_1.603883"></span>、<span id="stock_0.000915"><a href="http://quote.eastmoney.com/unify/r/0.000915" class="keytip" data-code="0,000915">华特达因</a></span><span id="quote_0.000915"></span>、<span id="stock_0.300294"><a href="http://quote.eastmoney.com/unify/r/0.300294" class="keytip" data-code="0,300294">博雅生物</a></span><span id="quote_0.300294"></span>。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121427849328&direct=1&abc4167.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.601236"><a href="http://quote.eastmoney.com/unify/r/1.601236" class="keytip" data-code="1,601236">红塔证券</a></span><span id="quote_1.601236"></span>：关注具备成熟基层销售体系的中药龙头和中药材资源控制权的中药企业</strong></p><p>我们认为未来三年我国医疗改革进入深水区，改革的核心方向是“县级医疗体系”。随着县级医联体和DRG/DIPs的全面推广，医疗机构的盈利模式和医护人员的薪酬核算将出现颠覆性改变，医疗新基建的设备采购意向将向性价比高的国产医疗设备倾斜。建议关注符合基层医疗临床需求医疗设备耗材，如部分便携式医疗诊断设备。</p><p>此外，中药配方颗粒试点放开，并纳入中药传统饮片管理，同时短期免疫DRG/DIPs政策。全国推广分级诊疗中明确了中医在基层医疗的地位，我们认为中医药在医改后期的发展方向将在基层医疗端。建议关注已经具备成熟基层销售体系的中药龙头企业和具有中药材资源控制权的中药企业。2月医药投资组合：<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="stock_0.300633"><a href="http://quote.eastmoney.com/unify/r/0.300633" class="keytip" data-code="0,300633">开立医疗</a></span><span id="quote_0.300633"></span>、<span id="stock_1.601607"><a href="http://quote.eastmoney.com/unify/r/1.601607" class="keytip" data-code="1,601607">上海医药</a></span><span id="quote_1.601607"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000999" class="em_stock_key_common" data-code="0,000999">华润三九</span>。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121440786498&direct=1&abc7118.pdf">【点击查看研报原文】</a></p><p><strong>开源<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：中药板块有望长期受益于政策 具备长期投资价值</strong></p><p>1月30日，工业和信息化部、国家发展和改革委员会、科学技术部等九部门联合印发《“十四五”医药工业发展规划》，中药板块有望长期受益。《规划》将中药纳入医药工业发展重点领域，表明我国重点发展中药产业的决心，中药板块有望长期受益于政策，具备长期投资价值；强调推进中药守正创新，加大投入力度支持开发创新产品，支持中医药传承创新发展，中药新药的获批有望进一步加速；强调重点开展基于古代经典名方中药复方制剂研制，以及医疗机构中药制剂向中药新药转化，鼓励对已上市中药的二次开发，发展中药大品种；鼓励企业“走出去”，加强与共建“一带一路”国家合作，开拓新市场，走出新的增长曲线。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220215121452864640&direct=1&abc6712.pdf">【点击查看研报原文】</a></p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300059" class="em_stock_key_common" data-code="0,300059">东方财富</span>研究中心）</p>

<http://stock.eastmoney.com/news/1405,202202152276885729.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)